Exploring Metabolic and Immunological Biomarkers for Oral Squamous Cell Carcinoma: Potential Targets for Precision Therapy
Authors:
- RajneeshRARajneesh
- Rahul TiwariRTRahul Tiwari
- Vishal Kumar SinghVSVishal Kumar Singh
- Awnish KumarAKAwnish Kumar
- Sanjana MehrotraSMSanjana Mehrotra
- Vibhav GautamVibhav Gautam
- J. F. NevilleJNJ. F. Neville
- Vyomika BansalVBVyomika Bansal
- Rajiv PathakRajiv Pathak
- Akhilesh Kumar SinghASAkhilesh Kumar Singh
- Rajiv KumarRKRajiv Kumar
Open Access
Abstract
Oral squamous cell carcinoma (OSCC) is a malignant neoplasm of the oral epithelium that constitutes majority of oral cancers and is strongly associated with risk factors such as tobacco use and genetic alterations. Mortality rates for OSCC are high because many cases are misdiagnosed or identified at later stages, and treatment options are limited with high recurrence. Therefore, there is an urgent need for improved diagnostic and therapeutic strategies. OSCC tumor cells, like those in other solid malignancies, exhibit significant alterations in metabolic pathways and the immune microenvironment. These changes can serve as valuable biomarkers for early detection and as targets for innovative treatment strategies. This review summarizes the current understanding of metabolic and immunological biomarkers that are either currently in use for OSCC or are in different phases of clinical trials.Keywords
Funding Information
- Institute of Eminence Grant of Banaras Hindu University (BHU-IoE)
- Office of Director, Institute of Medical Sciences, Banaras Hindu University
This publication has 200 references indexed in Scilit:
- Serum CXCL13 as a Novel Biomarker in Oral Squamous Cell CarcinomaCancer Medicine, 2024
- Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell CarcinomaAdvanced Science, 2023
- PD‐L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedsideClinical and Experimental Dental Research, 2022
- Cancer‐associated fibroblasts promote tumor progression by lncRNA‐mediated RUNX2/GDF10 signaling in oral squamous cell carcinomaMolecular Oncology, 2021
- ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine‐addicted OSCC cellsCancer Medicine, 2020
- RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF‐κB pathway in oral squamous cell carcinomaMolecular Oncology, 2020
- MUC1 as a target for CAR‐T therapy in head and neck squamous cell carinomaCancer Medicine, 2019
- Immune checkpoints and their inhibition in cancer and infectious diseasesEuropean Journal of Immunology, 2017
- Interleukin‐6 predicts recurrence and survival among head and neck cancer patientsCancer, 2008
- The relation between hypoxia‐inducible factor (HIF)‐1α and HIF‐2α expression with anemia and outcome in surgically treated head and neck cancerCancer, 2006